Total Payments
$22,170
2024 Payments
$436.46
Companies
46
Transactions
189
Medicare Patients
27,312
Medicare Billing
$6.0M
Payment Breakdown by Category
Consulting$13,971 (63.0%)
Other$4,225 (19.1%)
Food & Beverage$3,606 (16.3%)
Research$209.71 (0.9%)
Travel$136.74 (0.6%)
Education$22.26 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $13,971 | 8 | 63.0% |
| Honoraria | $4,225 | 2 | 19.1% |
| Food and Beverage | $3,606 | 173 | 16.3% |
| Unspecified | $209.71 | 1 | 0.9% |
| Travel and Lodging | $136.74 | 3 | 0.6% |
| Education | $22.26 | 2 | 0.1% |
Payments by Type
General
$21,961
188 transactions
Research
$209.71
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $4,050 | 1 | $0 (2021) |
| Deciphera Pharmaceuticals Inc. | $3,487 | 9 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,908 | 10 | $0 (2024) |
| Puma Biotechnology, Inc. | $2,399 | 3 | $0 (2018) |
| Bayer Healthcare Pharmaceuticals Inc. | $2,391 | 9 | $0 (2023) |
| Janssen Biotech, Inc. | $1,624 | 10 | $0 (2019) |
| TerSera Therapeutics LLC | $1,150 | 2 | $0 (2017) |
| NanoString Technologies, Inc. | $1,079 | 2 | $0 (2018) |
| BeiGene, Ltd. | $450.00 | 1 | $0 (2020) |
| Merck Sharp & Dohme LLC | $447.05 | 25 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $436.46 | 11 | Novartis Pharmaceuticals Corporation ($209.71) |
| 2023 | $868.35 | 11 | Bayer Healthcare Pharmaceuticals Inc. ($655.50) |
| 2022 | $3,649 | 14 | Deciphera Pharmaceuticals Inc. ($3,465) |
| 2021 | $4,062 | 2 | Lilly USA, LLC ($4,050) |
| 2020 | $3,253 | 8 | AstraZeneca Pharmaceuticals LP ($2,700) |
| 2019 | $3,753 | 41 | Bayer HealthCare Pharmaceuticals Inc. ($1,643) |
| 2018 | $4,258 | 49 | Puma Biotechnology, Inc. ($2,399) |
| 2017 | $1,890 | 53 | TerSera Therapeutics LLC ($1,150) |
All Payment Transactions
189 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $24.99 | General |
| Category: Hematology | ||||||
| 11/18/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $20.24 | General |
| Category: Rare Disease | ||||||
| 11/13/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $17.97 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $35.69 | General |
| Category: Oncology | ||||||
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $31.34 | General |
| 09/09/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | YONSA (Drug), Odomzo | Food and Beverage | In-kind items and services | $15.55 | General |
| Category: Oncology | ||||||
| 08/02/2024 | Pharmacosmos Therapeutics Inc. | COSELA (Drug) | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: HEMATOLOGY | ||||||
| 05/20/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $26.30 | General |
| Category: Hematology | ||||||
| 04/17/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $21.94 | General |
| Category: ONCOLOGY | ||||||
| 03/06/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $14.28 | General |
| Category: ONCOLOGY | ||||||
| 02/06/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | — | Cash or cash equivalent | $209.71 | Research |
| Study: HEOR - LEE011-2016-PLS • Category: Oncology | ||||||
| 11/22/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $30.01 | General |
| Category: Oncology | ||||||
| 11/20/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $28.33 | General |
| Category: Hematology | ||||||
| 10/11/2023 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug), PLUVICTO | Food and Beverage | In-kind items and services | $15.14 | General |
| Category: Oncology | ||||||
| 09/28/2023 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug) | Consulting Fee | Cash or cash equivalent | $655.50 | General |
| Category: Oncology | ||||||
| 09/27/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $26.30 | General |
| Category: Hematology | ||||||
| 08/30/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $19.58 | General |
| Category: ONCOLOGY | ||||||
| 08/23/2023 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $18.03 | General |
| Category: Oncology | ||||||
| 07/26/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $17.27 | General |
| Category: Hematology | ||||||
| 05/03/2023 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $15.33 | General |
| Category: Oncology | ||||||
| 04/11/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $23.20 | General |
| Category: ONCOLOGY | ||||||
| 01/30/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: Oncology | ||||||
| 11/14/2022 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $19.17 | General |
| Category: Oncology | ||||||
| 11/14/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.89 | General |
| Category: Oncology | ||||||
| 11/02/2022 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $19.78 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| HEOR - LEE011-2016-PLS | Novartis Pharmaceuticals Corporation | $209.71 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 76 | 6,532 | 173,783 | $2.8M | $1.4M |
| 2022 | 78 | 6,866 | 199,656 | $2.3M | $993,455 |
| 2021 | 83 | 6,796 | 197,558 | $2.6M | $1.3M |
| 2020 | 79 | 7,118 | 254,489 | $4.3M | $2.3M |
Total Patients
27,312
Total Services
825,486
Medicare Billing
$6.0M
Procedure Codes
316
All Medicare Procedures & Services
316 procedure records from CMS Medicare Utilization — Page 1 of 13
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 12 | 13,800 | $956,600 | $597,644 | 62.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 63 | 6,480 | $189,480 | $117,808 | 62.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 260 | 765 | $216,581 | $97,512 | 45.0% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 35 | 28,430 | $113,720 | $67,031 | 58.9% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 59 | 71,250 | $143,250 | $61,491 | 42.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 464 | 699 | $145,247 | $57,650 | 39.7% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 45 | 155 | $87,684 | $53,670 | 61.2% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 22 | 624 | $97,848 | $51,833 | 53.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 108 | 493 | $185,310 | $44,758 | 24.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 713 | 3,202 | $46,128 | $23,942 | 51.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 720 | 2,835 | $42,492 | $23,466 | 55.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 657 | 2,261 | $41,670 | $23,123 | 55.5% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 54 | 263 | $18,440 | $19,012 | 103.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 88 | 88 | $31,017 | $13,698 | 44.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 90 | 603 | $51,354 | $12,406 | 24.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 182 | 224 | $32,524 | $12,359 | 38.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 55 | 234 | $43,524 | $10,483 | 24.1% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 12 | 74 | $15,466 | $9,872 | 63.8% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 260 | 685 | $16,957 | $8,962 | 52.9% |
| J1442 | Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | Office | 2023 | 13 | 10,560 | $21,120 | $8,135 | 38.5% |
| 83521 | Measurement of immunoglobulin light chains | Office | 2023 | 73 | 467 | $14,010 | $7,904 | 56.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 92 | 176 | $32,783 | $7,192 | 21.9% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 20 | 142 | $35,545 | $6,748 | 19.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 46 | 46 | $11,914 | $5,324 | 44.7% |
| 83550 | Iron binding capacity | Office | 2023 | 249 | 635 | $9,855 | $5,320 | 54.0% |
About Dr. Yanjun Ma, M.D
Dr. Yanjun Ma, M.D is a Medical Oncology healthcare provider based in Murfreesboro, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/18/2007. The National Provider Identifier (NPI) number assigned to this provider is 1598973273.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Yanjun Ma, M.D has received a total of $22,170 in payments from pharmaceutical and medical device companies, with $436.46 received in 2024. These payments were reported across 189 transactions from 46 companies. The most common payment nature is "Consulting Fee" ($13,971).
As a Medicare-enrolled provider, Ma has provided services to 27,312 Medicare beneficiaries, totaling 825,486 services with total Medicare billing of $6.0M. Data is available for 4 years (2020–2023), covering 316 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Murfreesboro, TN
- Active Since 05/18/2007
- Last Updated 02/25/2014
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1598973273
Products in Payments
- QINLOCK (Drug) $3,487
- IMFINZI (Drug) $2,831
- Nerlynx (Drug) $2,399
- IMBRUVICA (Drug) $1,655
- Vitrakvi (Drug) $1,620
- ZOLADEX (Drug) $1,150
- PROSIGNA ASSAY (Device) $1,079
- Stivarga (Drug) $690.70
- BRUKINSA (Drug) $450.00
- KEYTRUDA (Biological) $447.05
- OPDIVO (Biological) $210.45
- KISQALI (Drug) $209.71
- XTANDI (Drug) $186.61
- IBRANCE (Drug) $125.89
- REBLOZYL (Biological) $98.20
- clonoSEQ (Device) $97.43
- Halaven (Drug) $86.74
- Neulasta (Biological) $76.70
- Xtandi (Drug) $69.86
- ZEJULA (Drug) $63.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.